Funding Received
$35 Million in 2 Rounds from 2 Investors
Most Recent Funding
$30 Million Series A on June 23, 2014
Cambridge, MA
Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases.

Company Details


Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Our team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases.

The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.

Current Team (1)


Funding Rounds (2) - $35M


Investors (2)

  • B1ce9d2887c930e2d5d82b64a7eebcb9

    OrbiMed Advisors

    OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under...
  • D3e1b3e814df8263aee6a5b51a21544d

    Fidelity Biosciences

    They are a division of Fidelity Investments, one of the world’s leading providers of financial...

Offices/Locations (1)

  • Office

    1 Main Street

    13th Floor

    Cambridge, MA 02142